Drivers and recent trends of hospitalisation costs related to acute pulmonary embolism
- PMID: 38565711
- DOI: 10.1007/s00392-024-02437-y
Drivers and recent trends of hospitalisation costs related to acute pulmonary embolism
Abstract
Background and aims: The socio-economic burden imposed by acute pulmonary embolism (PE) on European healthcare systems is largely unknown. We sought to determine temporal trends and identify cost drivers of hospitalisation for PE in Germany.
Methods and results: We analysed the totality of reimbursed hospitalisation costs in Germany (G-DRG system) in the years 2016-2020. Overall, 484 884 PE hospitalisations were coded in this period. Direct hospital costs amounted to a median of 3572 (IQR, 2804 to 5869) euros, resulting in average total reimbursements of 710 million euros annually. Age, PE severity, comorbidities and in-hospital (particularly bleeding) complications were identified by multivariable logistic regression as significant cost drivers. Use of catheter-directed therapy (CDT) constantly increased (annual change in the absolute proportion of hospitalisations with CDT + 0.40% [95% CI + 0.32% to + 0.47%]; P < 0.001), and it more than doubled in the group of patients with severe PE (28% of the entire population) over time. Although CDT use was overall associated with increased hospitalisation costs, this association was no longer present (adjusted OR 1.02 [0.80-1.31]) in patients with severe PE and shock; this was related, at least in part, to a reduction in the median length of hospital stay (for 14.0 to 8.0 days).
Conclusions: We identified current and emerging cost drivers of hospitalisation for PE, focusing on severe disease and intermediate/high risk of an adverse early outcome. The present study may inform reimbursement decisions by policymakers and help to guide future health economic analysis of advanced treatment options for patients with PE.
Keywords: Catheter-directed treatment; Cost of illness; Economic burden; Hospitalisation costs; Pulmonary embolism.
© 2024. The Author(s).
Similar articles
-
Modelling costs of interventional pulmonary embolism treatment: implications of US trends for a European healthcare system.Eur Heart J Acute Cardiovasc Care. 2024 Jun 30;13(6):501-505. doi: 10.1093/ehjacc/zuae019. Eur Heart J Acute Cardiovasc Care. 2024. PMID: 38349225 Free PMC article.
-
Cost-Comparison of Mechanical Thrombectomy and Catheter-Directed Thrombolysis in Intermediate-Risk Pulmonary Embolism.J Soc Cardiovasc Angiogr Interv. 2023 Oct 14;3(2):101187. doi: 10.1016/j.jscai.2023.101187. eCollection 2024 Feb. J Soc Cardiovasc Angiogr Interv. 2023. PMID: 39132209 Free PMC article.
-
Catheter-directed thrombolysis versus suction thrombectomy in the management of acute pulmonary embolism.J Vasc Surg Venous Lymphat Disord. 2019 Sep;7(5):623-628. doi: 10.1016/j.jvsv.2018.10.025. Epub 2019 Mar 20. J Vasc Surg Venous Lymphat Disord. 2019. PMID: 30902560
-
Catheter-Based Therapies Decrease Mortality in Patients With Intermediate and High-Risk Pulmonary Embolism: Evidence From Meta-Analysis of 65,589 Patients.Front Cardiovasc Med. 2022 Jun 16;9:861307. doi: 10.3389/fcvm.2022.861307. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35783825 Free PMC article.
-
Endovascular Management of Massive and Submassive Acute Pulmonary Embolism: Current Trends in Risk Stratification and Catheter-Directed Therapies.Curr Cardiol Rep. 2017 Jun;19(6):54. doi: 10.1007/s11886-017-0864-8. Curr Cardiol Rep. 2017. PMID: 28466280 Review.
Cited by
-
Time trends of catheter-directed treatment in acute pulmonary embolism in Germany.Res Pract Thromb Haemost. 2024 Dec 9;9(1):102651. doi: 10.1016/j.rpth.2024.102651. eCollection 2025 Jan. Res Pract Thromb Haemost. 2024. PMID: 39834528 Free PMC article.
-
Enhanced recovery and abbreviated length of anticoagulation for thromboprophylaxis after primary hip arthroplasty rationale and design of the ENABLE-hip trial.J Thromb Thrombolysis. 2025 Aug;58(6):689-698. doi: 10.1007/s11239-025-03110-5. Epub 2025 May 29. J Thromb Thrombolysis. 2025. PMID: 40442449 Free PMC article.
-
Intensive care treatment in acute pulmonary embolism in Germany, 2016 to 2020: a nationwide inpatient database study.Res Pract Thromb Haemost. 2024 Aug 8;8(6):102545. doi: 10.1016/j.rpth.2024.102545. eCollection 2024 Aug. Res Pract Thromb Haemost. 2024. PMID: 39318771 Free PMC article.
-
Estimated annual healthcare costs after acute pulmonary embolism: results from a prospective multicentre cohort study.Eur Heart J Qual Care Clin Outcomes. 2025 May 1;11(3):334-342. doi: 10.1093/ehjqcco/qcae050. Eur Heart J Qual Care Clin Outcomes. 2025. PMID: 38950900 Free PMC article.
References
-
- Wendelboe AM, Raskob GE (2016) Global burden of thrombosis: epidemiologic aspects. Circ Res 118:1340–1347. https://doi.org/10.1161/CIRCRESAHA.115.306841 - DOI - PubMed
-
- Barco S, Mahmoudpour SH, Valerio L, Klok FA, Munzel T, Middeldorp S, Ageno W, Cohen AT, Hunt BJ, Konstantinides SV (2020) Trends in mortality related to pulmonary embolism in the European Region, 2000–15: analysis of vital registration data from the WHO Mortality Database. Lancet Respir Med 8:277–287. https://doi.org/10.1016/S2213-2600(19)30354-6 - DOI - PubMed
-
- Martin KA, Molsberry R, Cuttica MJ, Desai KR, Schimmel DR, Khan SS (2020) Time trends in pulmonary embolism mortality rates in the United States, 1999 to 2018. J Am Heart Assoc 9:e016784. https://doi.org/10.1161/JAHA.120.016784 - DOI - PubMed - PMC
-
- Barco S, Valerio L, Ageno W, Cohen AT, Goldhaber SZ, Hunt BJ, Iorio A, Jimenez D, Klok FA, Kucher N, Mahmoudpour SH, Middeldorp S, Munzel T, Tagalakis V, Wendelboe AM, Konstantinides SV (2021) Age-sex specific pulmonary embolism-related mortality in the USA and Canada, 2000–18: an analysis of the WHO Mortality Database and of the CDC Multiple Cause of Death database. Lancet Respir Med 9:33–42. https://doi.org/10.1016/S2213-2600(20)30417-3 - DOI - PubMed
-
- Giri J, Sista AK, Weinberg I, Kearon C, Kumbhani DJ, Desai ND, Piazza G, Gladwin MT, Chatterjee S, Kobayashi T, Kabrhel C, Barnes GD (2019) Interventional therapies for acute pulmonary embolism: current status and principles for the development of novel evidence: a scientific statement from the American Heart Association. Circulation 140:e774–e801. https://doi.org/10.1161/CIR.0000000000000707 - DOI - PubMed
LinkOut - more resources
Full Text Sources